Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review

Uterine spiral artery remodeling is essential for placental perfusion and fetal growth and, when impaired, results in placental ischemia and pregnancy complications, e.g., fetal growth restriction, preeclampsia, premature birth. Despite the high incidence of adverse pregnancies, current treatment op...

Full description

Bibliographic Details
Main Authors: Gerald J. Pepe, Eugene D. Albrecht
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Genes
Subjects:
Online Access:https://www.mdpi.com/2073-4425/12/8/1255
id doaj-2f6f32790abd47bd9b94004720ed786e
record_format Article
spelling doaj-2f6f32790abd47bd9b94004720ed786e2021-08-26T13:47:07ZengMDPI AGGenes2073-44252021-08-01121255125510.3390/genes12081255Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A ReviewGerald J. Pepe0Eugene D. Albrecht1Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA 23507, USADepartments of Obstetrics/Gynecology/Reproductive Sciences and Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USAUterine spiral artery remodeling is essential for placental perfusion and fetal growth and, when impaired, results in placental ischemia and pregnancy complications, e.g., fetal growth restriction, preeclampsia, premature birth. Despite the high incidence of adverse pregnancies, current treatment options are limited. Accordingly, research has shifted to the development of gene therapy technologies that provide targeted delivery of “payloads” to the placenta while limiting maternal and fetal exposure. This review describes the current strategies, including placental targeting peptide-bound liposomes, nanoparticle or adenovirus constructs decorated with specific peptide sequences and placental gene promoters delivered via maternal IV injection, directly into the placenta or the uterine artery, as well as noninvasive site-selective targeting of regulating genes conjugated with microbubbles via contrast-enhanced ultrasound. The review also provides a perspective on the effectiveness of these technologies in various animal models and their practicability and potential use for targeted placental delivery of therapeutics and genes in adverse human pregnancies affected by placental dysfunction.https://www.mdpi.com/2073-4425/12/8/1255spiral artery remodelingpregnancy diseasesplacentapreeclampsiapeptide-mediated gene targetingtrophoblast-targeted nanoparticles
collection DOAJ
language English
format Article
sources DOAJ
author Gerald J. Pepe
Eugene D. Albrecht
spellingShingle Gerald J. Pepe
Eugene D. Albrecht
Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
Genes
spiral artery remodeling
pregnancy diseases
placenta
preeclampsia
peptide-mediated gene targeting
trophoblast-targeted nanoparticles
author_facet Gerald J. Pepe
Eugene D. Albrecht
author_sort Gerald J. Pepe
title Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
title_short Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
title_full Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
title_fullStr Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
title_full_unstemmed Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
title_sort novel technologies for target delivery of therapeutics to the placenta during pregnancy: a review
publisher MDPI AG
series Genes
issn 2073-4425
publishDate 2021-08-01
description Uterine spiral artery remodeling is essential for placental perfusion and fetal growth and, when impaired, results in placental ischemia and pregnancy complications, e.g., fetal growth restriction, preeclampsia, premature birth. Despite the high incidence of adverse pregnancies, current treatment options are limited. Accordingly, research has shifted to the development of gene therapy technologies that provide targeted delivery of “payloads” to the placenta while limiting maternal and fetal exposure. This review describes the current strategies, including placental targeting peptide-bound liposomes, nanoparticle or adenovirus constructs decorated with specific peptide sequences and placental gene promoters delivered via maternal IV injection, directly into the placenta or the uterine artery, as well as noninvasive site-selective targeting of regulating genes conjugated with microbubbles via contrast-enhanced ultrasound. The review also provides a perspective on the effectiveness of these technologies in various animal models and their practicability and potential use for targeted placental delivery of therapeutics and genes in adverse human pregnancies affected by placental dysfunction.
topic spiral artery remodeling
pregnancy diseases
placenta
preeclampsia
peptide-mediated gene targeting
trophoblast-targeted nanoparticles
url https://www.mdpi.com/2073-4425/12/8/1255
work_keys_str_mv AT geraldjpepe noveltechnologiesfortargetdeliveryoftherapeuticstotheplacentaduringpregnancyareview
AT eugenedalbrecht noveltechnologiesfortargetdeliveryoftherapeuticstotheplacentaduringpregnancyareview
_version_ 1721193128085422080